JP2002508356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002508356A5 JP2002508356A5 JP2000538990A JP2000538990A JP2002508356A5 JP 2002508356 A5 JP2002508356 A5 JP 2002508356A5 JP 2000538990 A JP2000538990 A JP 2000538990A JP 2000538990 A JP2000538990 A JP 2000538990A JP 2002508356 A5 JP2002508356 A5 JP 2002508356A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydroxy
- hydrogen
- pyridin
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 CThree-C8-Cycloalkyl Chemical group 0.000 description 326
- 229910052739 hydrogen Inorganic materials 0.000 description 139
- 239000001257 hydrogen Substances 0.000 description 139
- 150000002431 hydrogen Chemical class 0.000 description 110
- 125000003118 aryl group Chemical group 0.000 description 103
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 83
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 79
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 77
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 73
- 229910052757 nitrogen Inorganic materials 0.000 description 69
- 229910052760 oxygen Inorganic materials 0.000 description 66
- 125000000217 alkyl group Chemical group 0.000 description 65
- 229910052717 sulfur Inorganic materials 0.000 description 60
- 239000011737 fluorine Substances 0.000 description 57
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 55
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 48
- 229910052736 halogen Inorganic materials 0.000 description 48
- 150000002367 halogens Chemical class 0.000 description 48
- 125000004093 cyano group Chemical group *C#N 0.000 description 47
- 125000000623 heterocyclic group Chemical group 0.000 description 46
- 229910052731 fluorine Inorganic materials 0.000 description 36
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 33
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 33
- 125000004433 nitrogen atom Chemical group N* 0.000 description 33
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 33
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 33
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 32
- 125000006413 ring segment Chemical group 0.000 description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 29
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 27
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 27
- 125000005842 heteroatom Chemical group 0.000 description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 27
- 125000004076 pyridyl group Chemical group 0.000 description 27
- 125000003545 alkoxy group Chemical group 0.000 description 25
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 24
- 125000001624 naphthyl group Chemical group 0.000 description 24
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 22
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 21
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 20
- 125000001424 substituent group Chemical group 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 15
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 15
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 125000002619 bicyclic group Chemical group 0.000 description 13
- 125000004043 oxo group Chemical group O=* 0.000 description 13
- 125000000547 substituted alkyl group Chemical group 0.000 description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- 125000003368 amide group Chemical group 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 12
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 12
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 12
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 12
- 125000002541 furyl group Chemical group 0.000 description 12
- 125000002883 imidazolyl group Chemical group 0.000 description 12
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 12
- 125000001041 indolyl group Chemical group 0.000 description 12
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- 125000002971 oxazolyl group Chemical group 0.000 description 12
- 125000000335 thiazolyl group Chemical group 0.000 description 12
- 125000001544 thienyl group Chemical group 0.000 description 12
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 10
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 9
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 9
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 9
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 9
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 9
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 9
- 125000000842 isoxazolyl group Chemical group 0.000 description 9
- 125000001715 oxadiazolyl group Chemical group 0.000 description 9
- 125000003373 pyrazinyl group Chemical group 0.000 description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 125000004193 piperazinyl group Chemical group 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 6
- UKHJNJFJCGBKSF-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.1]heptane Chemical compound C1NC2CNC1C2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 description 6
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- VWBYXJRDIQCSLW-UHFFFAOYSA-N O=[P](c1ccccc1)c1ccccc1 Chemical group O=[P](c1ccccc1)c1ccccc1 VWBYXJRDIQCSLW-UHFFFAOYSA-N 0.000 description 6
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 6
- 125000004423 acyloxy group Chemical group 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 6
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 6
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 6
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 6
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 6
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 6
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 6
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 6
- 125000005945 imidazopyridyl group Chemical group 0.000 description 6
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 6
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 6
- 125000001786 isothiazolyl group Chemical group 0.000 description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 125000002098 pyridazinyl group Chemical group 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 6
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- LBUJPTNKIBCYBY-UHFFFAOYSA-N tetrahydroquinoline Natural products C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 6
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 description 6
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 6
- 125000004306 triazinyl group Chemical group 0.000 description 6
- 125000001425 triazolyl group Chemical group 0.000 description 6
- 0 C*CC(*)C(N=C)=C Chemical compound C*CC(*)C(N=C)=C 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
- 125000006823 (C1-C6) acyl group Chemical group 0.000 description 3
- CVEXTAUZJWYDJX-UHFFFAOYSA-N 1,3,4,10-Tetrahydro-9(2H)-acridinone Chemical compound N1C2=CC=CC=C2C(=O)C2=C1CCCC2 CVEXTAUZJWYDJX-UHFFFAOYSA-N 0.000 description 3
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 3
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 3
- SHDIFTVYQLNRLR-UHFFFAOYSA-N 11h-pyrido[3,2-b][1]benzazepine Chemical compound C1=CC2=NC=CC=C2NC2=CC=CC=C21 SHDIFTVYQLNRLR-UHFFFAOYSA-N 0.000 description 3
- MGEHZOOOVVSDAU-UHFFFAOYSA-N 1h-pyrido[2,3-b][1,4]diazepine Chemical compound N1C=CC=NC2=NC=CC=C12 MGEHZOOOVVSDAU-UHFFFAOYSA-N 0.000 description 3
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 3
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 3
- DJWDAKFSDBOQJK-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.2]octane Chemical compound C1NC2CCC1NC2 DJWDAKFSDBOQJK-UHFFFAOYSA-N 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 3
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical compound C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 3
- COMRSYCVLKBODY-UHFFFAOYSA-N 3-pyridin-3-yl-n-[4-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl]prop-2-enamide Chemical compound C1CN(C2C3=CC=CC=C3CCC2)CCN1CCCCNC(=O)C=CC1=CC=CN=C1 COMRSYCVLKBODY-UHFFFAOYSA-N 0.000 description 3
- PZYHBBYPOVMRAY-UHFFFAOYSA-N 3-pyridin-3-yl-n-[4-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl]prop-2-enamide Chemical compound C1CN(C=2C=3CCCCC=3C=CC=2)CCN1CCCCNC(=O)C=CC1=CC=CN=C1 PZYHBBYPOVMRAY-UHFFFAOYSA-N 0.000 description 3
- RUOPWDVFAXCKCF-UHFFFAOYSA-N 4-[4-[4-(3-pyridin-3-ylprop-2-enoylamino)butyl]piperazine-1-carbonyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)N1CCN(CCCCNC(=O)C=CC=2C=NC=CC=2)CC1 RUOPWDVFAXCKCF-UHFFFAOYSA-N 0.000 description 3
- LMSDNEUOCUNNFM-UHFFFAOYSA-N 4-[phenyl-[4-[4-(3-pyridin-3-ylprop-2-enoylamino)butyl]piperazin-1-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C=1C=CC=CC=1)N1CCN(CCCCNC(=O)C=CC=2C=NC=CC=2)CC1 LMSDNEUOCUNNFM-UHFFFAOYSA-N 0.000 description 3
- WYVFAIDIZFAWMI-UHFFFAOYSA-N 5-azabicyclo[2.1.1]hexane Chemical compound C1CC2CC1N2 WYVFAIDIZFAWMI-UHFFFAOYSA-N 0.000 description 3
- VIQDTRXYTKXIMM-UHFFFAOYSA-N 5h-benzo[d][1]benzazepine Chemical compound N1C=CC2=CC=CC=C2C2=CC=CC=C12 VIQDTRXYTKXIMM-UHFFFAOYSA-N 0.000 description 3
- SNZSSCZJMVIOCR-UHFFFAOYSA-N 7-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1N2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 description 3
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 3
- ATPGYYPVVKZFGR-UHFFFAOYSA-N 9-azabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1N2 ATPGYYPVVKZFGR-UHFFFAOYSA-N 0.000 description 3
- ZWLTVCCOYCMAIM-UHFFFAOYSA-N 9h-pyrido[2,3-b]azepine Chemical compound C1=CC=CN=C2NC=CC=C21 ZWLTVCCOYCMAIM-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DWVHXGDHRMZZJF-UHFFFAOYSA-N N-[4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]but-2-ynyl]-3-pyridin-3-ylprop-2-enamide Chemical compound FC1=CC=C(C=C1)C(N1CCN(CC1)CC#CCNC(C=CC=1C=NC=CC=1)=O)C1=CC=C(C=C1)F DWVHXGDHRMZZJF-UHFFFAOYSA-N 0.000 description 3
- VETZQUSVLXLLPE-UHFFFAOYSA-N N1=CC=CC=C2NC=CC=C21 Chemical compound N1=CC=CC=C2NC=CC=C21 VETZQUSVLXLLPE-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000003302 alkenyloxy group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- 125000002785 azepinyl group Chemical group 0.000 description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 3
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 3
- 125000005870 benzindolyl group Chemical group 0.000 description 3
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 125000000638 benzylaminocarbonyl group Chemical group C(C1=CC=CC=C1)NC(=O)* 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 3
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 3
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 3
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- GJRBOOBAXCGJQY-UHFFFAOYSA-N n,n-diphenyl-4-[4-(3-pyridin-3-ylprop-2-enoylamino)butyl]piperazine-1-carboxamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCCN(CC1)CCN1C(=O)N(C=1C=CC=CC=1)C1=CC=CC=C1 GJRBOOBAXCGJQY-UHFFFAOYSA-N 0.000 description 3
- VYOWHSVUJZPJEH-UHFFFAOYSA-N n-[2-[2-(4-benzhydrylpiperazin-1-yl)ethoxy]ethyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCOCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 VYOWHSVUJZPJEH-UHFFFAOYSA-N 0.000 description 3
- VWUIDGCQCZSOTI-UHFFFAOYSA-N n-[2-[4-(6,11-dihydrobenzo[c][1]benzothiepin-11-yl)piperazin-1-yl]ethyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C2C3=CC=CC=C3SCC3=CC=CC=C32)CCN1CCNC(=O)C=CC1=CC=CN=C1 VWUIDGCQCZSOTI-UHFFFAOYSA-N 0.000 description 3
- ZRQFPVUHZSYAPT-UHFFFAOYSA-N n-[3-(4-benzhydrylpiperazin-1-yl)propoxy]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NOCCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 ZRQFPVUHZSYAPT-UHFFFAOYSA-N 0.000 description 3
- OPMSUJVKFJTEBW-UHFFFAOYSA-N n-[3-(4-benzhydrylpiperazin-1-yl)sulfonylpropyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCS(=O)(=O)N(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 OPMSUJVKFJTEBW-UHFFFAOYSA-N 0.000 description 3
- ZFQHABVBZYMUHQ-UHFFFAOYSA-N n-[4-(4-benzhydrylpiperazin-1-yl)-3-hydroxybutyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1CC(O)CCNC(=O)C=CC1=CC=CN=C1 ZFQHABVBZYMUHQ-UHFFFAOYSA-N 0.000 description 3
- BPEHUHLANPRGPA-UHFFFAOYSA-N n-[4-(4-benzhydrylpiperazin-1-yl)-4-oxobutyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCC(=O)N(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BPEHUHLANPRGPA-UHFFFAOYSA-N 0.000 description 3
- PUSSBYQCSZCMTI-UHFFFAOYSA-N n-[4-(4-benzoylpiperazin-1-yl)butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCCN(CC1)CCN1C(=O)C1=CC=CC=C1 PUSSBYQCSZCMTI-UHFFFAOYSA-N 0.000 description 3
- RWTPAANJPIVHRA-UHFFFAOYSA-N n-[4-(4-diphenylphosphorylpiperazin-1-yl)butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCCN(CC1)CCN1P(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 RWTPAANJPIVHRA-UHFFFAOYSA-N 0.000 description 3
- BLOSBAHOXPFMPY-UHFFFAOYSA-N n-[4-(4-naphthalen-1-ylpiperazin-1-yl)butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C=2C3=CC=CC=C3C=CC=2)CCN1CCCCNC(=O)C=CC1=CC=CN=C1 BLOSBAHOXPFMPY-UHFFFAOYSA-N 0.000 description 3
- OOABQFDYKHFVHE-UHFFFAOYSA-N n-[4-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CCN1CCCCNC(=O)C=CC1=CC=CN=C1 OOABQFDYKHFVHE-UHFFFAOYSA-N 0.000 description 3
- DFDWGAJVQZUYCS-UHFFFAOYSA-N n-[4-[4-(2,2-diphenylacetyl)piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCCN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 DFDWGAJVQZUYCS-UHFFFAOYSA-N 0.000 description 3
- VFDMQKPNEYXGKM-UHFFFAOYSA-N n-[4-[4-(2-aminobenzoyl)piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound NC1=CC=CC=C1C(=O)N1CCN(CCCCNC(=O)C=CC=2C=NC=CC=2)CC1 VFDMQKPNEYXGKM-UHFFFAOYSA-N 0.000 description 3
- HXDTVDXODIWBQJ-UHFFFAOYSA-N n-[4-[4-(2-phenylbenzoyl)piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCCN(CC1)CCN1C(=O)C1=CC=CC=C1C1=CC=CC=C1 HXDTVDXODIWBQJ-UHFFFAOYSA-N 0.000 description 3
- JWCCGNPZMJOHJI-UHFFFAOYSA-N n-[4-[4-(2-phenylphenyl)piperazin-1-yl]butyl]-2-pyridin-3-yloxyacetamide Chemical compound C1CN(C=2C(=CC=CC=2)C=2C=CC=CC=2)CCN1CCCCNC(=O)COC1=CC=CN=C1 JWCCGNPZMJOHJI-UHFFFAOYSA-N 0.000 description 3
- WPZIIEOXPLWRBK-UHFFFAOYSA-N n-[4-[4-(2-phenylphenyl)piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCCN(CC1)CCN1C1=CC=CC=C1C1=CC=CC=C1 WPZIIEOXPLWRBK-UHFFFAOYSA-N 0.000 description 3
- UKZKBHKWOLQCEJ-UHFFFAOYSA-N n-[4-[4-(2-phenylphenyl)piperazin-1-yl]butyl]-3-pyridin-3-ylpropanamide Chemical compound C1CN(C=2C(=CC=CC=2)C=2C=CC=CC=2)CCN1CCCCNC(=O)CCC1=CC=CN=C1 UKZKBHKWOLQCEJ-UHFFFAOYSA-N 0.000 description 3
- ALCHSXXBPJKGIR-UHFFFAOYSA-N n-[4-[4-(2-phenylphenyl)piperazin-1-yl]butyl]-5-pyridin-3-ylpenta-2,4-dienamide Chemical compound C=1C=CN=CC=1C=CC=CC(=O)NCCCCN(CC1)CCN1C1=CC=CC=C1C1=CC=CC=C1 ALCHSXXBPJKGIR-UHFFFAOYSA-N 0.000 description 3
- PAWUMBNDXBALGO-UHFFFAOYSA-N n-[4-[4-(6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulen-11-yl)piperazin-1-yl]butyl]-3-pyridin-3-ylpropanamide Chemical compound C1CN(C2C3=CC=CC=C3CCC3=CC=CC=C32)CCN1CCCCNC(=O)CCC1=CC=CN=C1 PAWUMBNDXBALGO-UHFFFAOYSA-N 0.000 description 3
- YHVQVTILSIGIDE-UHFFFAOYSA-N n-[4-[4-(6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulen-11-yl)piperazin-1-yl]butyl]-5-pyridin-3-ylpenta-2,4-dienamide Chemical compound C1CN(C2C3=CC=CC=C3CCC3=CC=CC=C32)CCN1CCCCNC(=O)C=CC=CC1=CC=CN=C1 YHVQVTILSIGIDE-UHFFFAOYSA-N 0.000 description 3
- XHYZWVLPROZKQN-UHFFFAOYSA-N n-[4-[4-(9-oxofluorene-4-carbonyl)piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C(=O)C=2C=3C4=CC=CC=C4C(=O)C=3C=CC=2)CCN1CCCCNC(=O)C=CC1=CC=CN=C1 XHYZWVLPROZKQN-UHFFFAOYSA-N 0.000 description 3
- IDOPKYFPTSRLMS-UHFFFAOYSA-N n-[4-[4-(9h-fluoren-9-yl)piperazin-1-yl]butyl]-2-pyridin-3-yloxyacetamide Chemical compound C1CN(C2C3=CC=CC=C3C3=CC=CC=C32)CCN1CCCCNC(=O)COC1=CC=CN=C1 IDOPKYFPTSRLMS-UHFFFAOYSA-N 0.000 description 3
- DXIRALBVLZPMSQ-UHFFFAOYSA-N n-[4-[4-(furan-2-carbonyl)piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCCN(CC1)CCN1C(=O)C1=CC=CO1 DXIRALBVLZPMSQ-UHFFFAOYSA-N 0.000 description 3
- YINZYZWIBJJCMX-UHFFFAOYSA-N n-[4-[4-[(4-aminophenyl)-phenylmethyl]piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1=CC(N)=CC=C1C(C=1C=CC=CC=1)N1CCN(CCCCNC(=O)C=CC=2C=NC=CC=2)CC1 YINZYZWIBJJCMX-UHFFFAOYSA-N 0.000 description 3
- HOWWNDCNPJNBIH-UHFFFAOYSA-N n-[5-[4-(2-phenylphenyl)piperazin-1-yl]pentyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCCCN(CC1)CCN1C1=CC=CC=C1C1=CC=CC=C1 HOWWNDCNPJNBIH-UHFFFAOYSA-N 0.000 description 3
- QEPNKFLQCNKHEM-UHFFFAOYSA-N n-[5-[4-(6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulen-11-yl)piperazin-1-yl]pentyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C2C3=CC=CC=C3CCC3=CC=CC=C32)CCN1CCCCCNC(=O)C=CC1=CC=CN=C1 QEPNKFLQCNKHEM-UHFFFAOYSA-N 0.000 description 3
- APQDKPOIOQNUBU-UHFFFAOYSA-N n-[5-[4-(9h-fluoren-9-yl)piperazin-1-yl]pentyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C2C3=CC=CC=C3C3=CC=CC=C32)CCN1CCCCCNC(=O)C=CC1=CC=CN=C1 APQDKPOIOQNUBU-UHFFFAOYSA-N 0.000 description 3
- PLZHREALXXJWTB-UHFFFAOYSA-N n-[6-[4-(2-phenylphenyl)piperazin-1-yl]hexyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C=1C=CN=CC=1C=CC(=O)NCCCCCCN(CC1)CCN1C1=CC=CC=C1C1=CC=CC=C1 PLZHREALXXJWTB-UHFFFAOYSA-N 0.000 description 3
- MMTIFNOYPVXYLB-UHFFFAOYSA-N n-[6-[4-(6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulen-11-yl)piperazin-1-yl]hexyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C2C3=CC=CC=C3CCC3=CC=CC=C32)CCN1CCCCCCNC(=O)C=CC1=CC=CN=C1 MMTIFNOYPVXYLB-UHFFFAOYSA-N 0.000 description 3
- QSHOXQHLHHLYFP-UHFFFAOYSA-N n-[6-[4-(9h-fluoren-9-yl)piperazin-1-yl]hexyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C2C3=CC=CC=C3C3=CC=CC=C32)CCN1CCCCCCNC(=O)C=CC1=CC=CN=C1 QSHOXQHLHHLYFP-UHFFFAOYSA-N 0.000 description 3
- HLMSEQWISJOZRY-UHFFFAOYSA-N n-naphthalen-1-yl-4-[4-(3-pyridin-3-ylpropanoylamino)butyl]piperazine-1-carboxamide Chemical compound C1CN(C(=O)NC=2C3=CC=CC=C3C=CC=2)CCN1CCCCNC(=O)CCC1=CC=CN=C1 HLMSEQWISJOZRY-UHFFFAOYSA-N 0.000 description 3
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 3
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 3
- 125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 description 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 3
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 3
- 125000005561 phenanthryl group Chemical group 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 3
- JDEUSZPWWMACHZ-UHFFFAOYSA-N pyrido[2,3-e][1,4]diazepin-5-one Chemical compound O=C1N=CC=NC2=NC=CC=C12 JDEUSZPWWMACHZ-UHFFFAOYSA-N 0.000 description 3
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 3
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 3
- 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 description 3
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 3
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- MSPKFNJUVWXLCH-UHFFFAOYSA-N n-[4-[4-(6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulen-11-yl)piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C2C3=CC=CC=C3CCC3=CC=CC=C32)CCN1CCCCNC(=O)C=CC1=CC=CN=C1 MSPKFNJUVWXLCH-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000021559 Dicerandra Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- TUZOVDPUVJVOFJ-UHFFFAOYSA-N n-[4-[4-(9h-fluoren-9-yl)piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide Chemical compound C1CN(C2C3=CC=CC=C3C3=CC=CC=C32)CCN1CCCCNC(=O)C=CC1=CC=CN=C1 TUZOVDPUVJVOFJ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19756236A DE19756236A1 (de) | 1997-12-17 | 1997-12-17 | Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE19756236.1 | 1997-12-17 | ||
| PCT/EP1998/008268 WO1999031063A1 (en) | 1997-12-17 | 1998-12-16 | New piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011152041A Division JP2011251976A (ja) | 1997-12-17 | 2011-07-08 | ピペラジニル−置換ピリジルアルカン、アルケンおよびアルキンカルボキサミド類 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002508356A JP2002508356A (ja) | 2002-03-19 |
| JP2002508356A5 true JP2002508356A5 (https=) | 2006-02-09 |
| JP4855576B2 JP4855576B2 (ja) | 2012-01-18 |
Family
ID=7852332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000538990A Expired - Fee Related JP4855576B2 (ja) | 1997-12-17 | 1998-12-16 | ピペラジニル−置換ピリジルアルカン、アルケンおよびアルキンカルボキサミド類 |
| JP2011152041A Pending JP2011251976A (ja) | 1997-12-17 | 2011-07-08 | ピペラジニル−置換ピリジルアルカン、アルケンおよびアルキンカルボキサミド類 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011152041A Pending JP2011251976A (ja) | 1997-12-17 | 2011-07-08 | ピペラジニル−置換ピリジルアルカン、アルケンおよびアルキンカルボキサミド類 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1060163B1 (https=) |
| JP (2) | JP4855576B2 (https=) |
| AT (1) | ATE306473T1 (https=) |
| AU (1) | AU2054399A (https=) |
| DE (2) | DE19756236A1 (https=) |
| DK (1) | DK1060163T3 (https=) |
| ES (1) | ES2251794T3 (https=) |
| WO (1) | WO1999031063A1 (https=) |
| ZA (1) | ZA9811235B (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19756236A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| AU5296799A (en) * | 1998-08-03 | 2000-02-28 | N-Gene Kutato Kft. | Pharmaceutical compositions against autoimmune diseases |
| UA65635C2 (uk) * | 1998-09-03 | 2004-04-15 | Н-Гене Кутато Кфт. | НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ |
| EP1031564A1 (en) | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
| HUP0103987A3 (en) * | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
| DE10152005A1 (de) | 2001-10-22 | 2003-04-30 | Bayer Cropscience Ag | Pyrazolylsubstituierte Heterocyclen |
| EP1348434A1 (en) * | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| WO2003099272A1 (en) | 2002-05-22 | 2003-12-04 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| JP5688367B2 (ja) | 2008-08-29 | 2015-03-25 | トポターゲット・アクティーゼルスカブＴｏｐｏＴａｒｇｅｔ Ａ／Ｓ | 新規なウレアおよびチオウレア誘導体 |
| WO2010066709A1 (en) * | 2008-12-09 | 2010-06-17 | Topotarget A/S | Novel pyridinyl acrylamide derivatives |
| CA2768338A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| PE20140011A1 (es) | 2010-09-03 | 2014-01-31 | Forma Tm Llc | Compuestos y composiciones novedosos para la inhibicion de nampt |
| JP6038792B2 (ja) | 2010-09-03 | 2016-12-07 | フォーマ ティーエム， エルエルシー． | 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体 |
| CN106243023A (zh) | 2010-09-03 | 2016-12-21 | 福马Tm有限责任公司 | 用于抑制nampt的胍化合物和组合物 |
| RU2017112522A (ru) | 2011-05-04 | 2019-01-24 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| WO2012154194A1 (en) | 2011-05-09 | 2012-11-15 | Forma Tm, Llc | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt) |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| CA2915357C (en) | 2013-06-14 | 2023-10-03 | Invictus Oncology Pvt. Ltd. | Lipid-based platinum compounds and nanoparticles |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| ES2826443T3 (es) * | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| MX2021000887A (es) | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
| CN109485646A (zh) * | 2018-12-12 | 2019-03-19 | 中国药科大学 | 一种苯并噻唑醌类化合物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8005133A (nl) * | 1980-09-12 | 1982-04-01 | Duphar Int Res | Fenylpiperazinederivaten met antiagressieve werking. |
| JPS57136518A (en) * | 1981-02-18 | 1982-08-23 | Eisai Co Ltd | Immunoregulator |
| US4778796A (en) * | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| EP0750496A1 (en) * | 1994-03-14 | 1997-01-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
| DE19624659A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19756236A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
-
1997
- 1997-12-17 DE DE19756236A patent/DE19756236A1/de not_active Ceased
-
1998
- 1998-12-08 ZA ZA9811235A patent/ZA9811235B/xx unknown
- 1998-12-16 AU AU20543/99A patent/AU2054399A/en not_active Abandoned
- 1998-12-16 DE DE69831877T patent/DE69831877T2/de not_active Expired - Lifetime
- 1998-12-16 JP JP2000538990A patent/JP4855576B2/ja not_active Expired - Fee Related
- 1998-12-16 EP EP98965275A patent/EP1060163B1/en not_active Expired - Lifetime
- 1998-12-16 AT AT98965275T patent/ATE306473T1/de active
- 1998-12-16 WO PCT/EP1998/008268 patent/WO1999031063A1/en not_active Ceased
- 1998-12-16 DK DK98965275T patent/DK1060163T3/da active
- 1998-12-16 ES ES98965275T patent/ES2251794T3/es not_active Expired - Lifetime
-
2011
- 2011-07-08 JP JP2011152041A patent/JP2011251976A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002508356A5 (https=) | ||
| RU2200734C2 (ru) | Амиды пиридилалкеновых и пиридилалкиновых кислот, способы их получения, фармацевтическая композиция на их основе и способ ее получения | |
| US4355036A (en) | Tricyclic-substituted piperidine antihistamines | |
| RU99101069A (ru) | Амиды пиридилалкеновых и пиридилалкиновых кислот в качестве цитостатиков и иммуносупрессорных агентов | |
| US4282233A (en) | Antihistaminic 11-(4-piperidylidene)-5H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridines | |
| JP2003525853A5 (https=) | ||
| AU2020341708B2 (en) | RIP1 inhibitory compounds and methods for making and using the same | |
| JP4855576B2 (ja) | ピペラジニル−置換ピリジルアルカン、アルケンおよびアルキンカルボキサミド類 | |
| CA2980800C (en) | Pyrazole compounds and method for making and using the compounds | |
| EP0912176B1 (en) | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | |
| EP0934309B1 (en) | New pyridyl alkane acid amides as cytostatics and immunosuppressives | |
| ES2262254T3 (es) | Piridil-alcano, -alqueno y -alquino sustituido con pireridinilo-carboxamidas como agentes citostaticos e inmunosupresores. | |
| US7232825B2 (en) | Phenylaminopyrimidine derivatives and methods of use | |
| JP2002508357A5 (https=) | ||
| CA2916419C (en) | Substituted 2, 3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | |
| JP2002508357A (ja) | 細胞増殖抑制剤及び免疫抑制剤として有用なアリール−置換ピリジルアルカン、アルケン及びアルキンカルボキサミド類 | |
| WO2009121535A2 (en) | Antiproliferative compounds and therapeutic uses thereof | |
| CA2943824A1 (en) | Inhibitors of histone demethylases | |
| NO310236B1 (no) | Nye 2,3-diokso-1,2,3,4-tetrahydro-quinoksalinylderivater og farmasöytisk sammensetning omfattende samme | |
| KR960010346B1 (ko) | 4(3h)-퀴나졸리논 유도체, 이의 제조방법 및 약제학적 조성물 | |
| JPWO1991001979A1 (ja) | 新規アミノピペラジン誘導体 | |
| JPH0780873B2 (ja) | 抗精神病薬，２‐（４‐ブチルピペラジン‐１‐イル）ピリジン類の環状イミド誘導体 | |
| CN105008347A (zh) | 作为钾离子通道抑制剂的异喹啉类化合物 | |
| JPH05504578A (ja) | 薬学組成物 | |
| JP2005097276A (ja) | 縮合ピリミジン誘導体およびその用途 |